{
    "clinical_study": {
        "@rank": "126100", 
        "acronym": "PAI", 
        "arm_group": [
            {
                "arm_group_label": "Integral Attention Program (PAI)", 
                "arm_group_type": "Experimental", 
                "description": "The key points of the PAI are:\nTo assess and manage pain and other symptoms resulting from disease progression.\nTo evaluate the information needs that may arise and to address them.\nTo encourage patient and family adaptation to the situation of advanced disease and in the terminal phase of it.\nTo provide guidance in decision-making while respecting patient autonomy.\nTo establish a plan of care and treatment, adapted to the evolution and needs of the patient.\nTo promote continuity of care."
            }, 
            {
                "arm_group_label": "Standard Palliative Chemotherapy and PAI", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard palliative chemotherapy will be administered, depending on type of cancer, as well as PAI as been defined above."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this clinical trial is to compare a non-pharmaceutical intervention (Integral\n      Attention Program or PAI) versus standard palliative chemotherapy treatment plus PAI in\n      patients with advanced cancer who have already received at least a first course of\n      chemotherapy but had proven therapeutic failure.\n\n      The study hypothesis is that palliative chemotherapy offers no clear benefits in relation to\n      quality-of-life-adjusted survival compared to a comprehensive care program."
        }, 
        "brief_title": "Integral Attention Program With or Without Palliative Chemotherapy in Advanced Cancer Patients", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cancer", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women \u226518 years of age.\n\n          -  Patients potentially eligible to receive a new chemotherapy cycle and whose clinical\n             condition, according to the oncologist, does not identify any therapeutic strategy\n             clearly superior to another, in the light of scientific evidence.\n\n          -  Patients with advanced cancers that have been treated with chemotherapy but who have\n             not displayed complete response to treatment or who, after treatment response, are\n             now in a situation of recurrence or disease progression\n\n          -  Patients who have previously received at least one chemotherapy cycle of the\n             following tumors:\n\n               -  Cancer of the digestive and gastrointestinal tract\n\n               -  Head and Neck Cancer\n\n               -  Lung cancer\n\n               -  Urologic cancers\n\n               -  Gynecologic cancers\n\n               -  Central nervous system cancer\n\n               -  Melanoma\n\n          -  Patients who can potentially comply with study and/or monitoring procedures and to\n             accept and sign the informed consent form.\n\n          -  Patients whose home is located less than 10 km, approximately, of the hospitals\n             participating in the study.\n\n        Exclusion Criteria:\n\n          -  Patients who are currently receiving chemotherapy, although patient pursuing any\n             other concomitant treatment are eligible (eg, hormone therapy or radiation therapy).\n\n          -  Patients who have contraindications to chemotherapy.\n\n          -  Patients who did not agree to participate in the clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01949974", 
            "org_study_id": "IIBSP-PAI-2011-36", 
            "secondary_id": [
                "2012-001128-36", 
                "PI11/01366"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Standard Palliative Chemotherapy and PAI", 
                "description": "Standard Palliative Chemotherapy, depending on type cancer.", 
                "intervention_name": "Standard Palliative Chemotherapy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Integral Attention Program (PAI)", 
                    "Standard Palliative Chemotherapy and PAI"
                ], 
                "description": "The PAI is a plan of care and treatment adapted in accordance with the evolution and needs of patients. This plan includes an initial comprehensive assessment of patients and their families during the first visit, including specialized psychological and social support when needed, voluntary art therapy and/or mindfulness. There will be outpatient monitoring, 24h phone assistance, home visits, support should hospitalization be required, and unscheduled visits by a palliative care team.", 
                "intervention_name": "Integral Attention Program (PAI)", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Palliative Chemotherapy", 
            "Integral Attention Program", 
            "Advanced cancer", 
            "Randomized Clinical Trial"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hospitalet de Llobregat", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08906"
                    }, 
                    "name": "Hospital General de l'Hospitalet de Llobregat"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sabadell", 
                        "country": "Spain", 
                        "state": "Barcelona"
                    }, 
                    "name": "Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08025"
                    }, 
                    "name": "Hospital de la Santa Creu i Sant Pau"
                }
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Integral Attention Program With or Without Palliative Chemotherapy in Advanced Cancer Patients: A Randomized Multicenter Clinical Trial", 
        "overall_official": {
            "affiliation": "Palliative Unit. Clinical Oncology Service. Hospital de la Santa Creu i Sant Pau. Barcelona. Spain.", 
            "last_name": "Antonio Pascual, Dr., PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Quality of life will be measured by the EuroQoL-5D questionnaire.", 
            "measure": "Survival adjusted for quality of life", 
            "safety_issue": "No", 
            "time_frame": "At one year of follow-up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01949974"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Specific Quality of life: measured through the quality of life questionnaire of the European Organisation for Research and Treatment of Cancer (EORTC QLQ C-30) and Palliative Care Scale (POS)", 
                "safety_issue": "No", 
                "time_frame": "At one year of follow-up"
            }, 
            {
                "measure": "Control of symptoms using the Edmonton Symptom Assessment System", 
                "safety_issue": "No", 
                "time_frame": "At one year of follow-up"
            }, 
            {
                "measure": "Toxicity by the American National Cancer Institute toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "At one year of follow-up"
            }, 
            {
                "measure": "Patient satisfaction regarding care using a Likert scale of 5 items (very satisfied, satisfied, neither satisfied or dissatisfied, somewhat satisfied and not satisfied).", 
                "safety_issue": "No", 
                "time_frame": "At one year of follow-up"
            }, 
            {
                "measure": "Costs reported by the information system of each hospital", 
                "safety_issue": "No", 
                "time_frame": "At the end of follow-up"
            }, 
            {
                "measure": "Adverse effects related to study interventions", 
                "safety_issue": "Yes", 
                "time_frame": "At one year of follow-up"
            }
        ], 
        "source": "Fundaci\u00f3 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fundaci\u00f3 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "August 2013", 
        "why_stopped": "Dificulties in the recruitment of patients."
    }
}